Avid Bioservices Inc (CDMO)

[itsabouttime]

Per example below taken out of an article this morning. Any feasibility of continuation after data analysis for SUNRISE?



Companies with the smallest market valuations are either poorly financed or have already endured some major setback. Cyclacel's phase III study has, for example, already failed its interim analysis, but in its case, the data safety monitoring board requested that the study continue to completion. Other companies might effectively be repeating a previously failed study with some minor changes, as is the case with Celsion.